Our formulations are informed by 47 peer-reviewed studies across three areas of pharmacological research: cannabinoid pharmacokinetics, lipid-based oral absorption, and the specific botanical ingredients in each ritual. Here is what the literature says, and how to read it.
Conventional oral cannabinoid formulations face a well-documented pharmacokinetic challenge. The majority of an oral dose is lost to first-pass hepatic metabolism before it can reach systemic circulation. Published human data place oral cannabinoid bioavailability in the range of approximately 6% to 19%.
Two foundational reviews summarize the evidence: Huestis (2007) and Millar et al. (2018). Together they establish the pharmacokinetic baseline against which every modern oral cannabinoid formulation is measured.
The science of improving this is the work the field is now doing. So is the work we built Axon Ritual to do.
NATURIA PLUS™ is a milk fat globule (MFG) based self-emulsifying delivery system. Lipophilic cannabinoids are encapsulated inside the lipid core of milk fat globule structures, the same biological vehicles mammals have evolved to absorb fat-soluble nutrients efficiently from infancy onward.
The pharmacokinetic significance lies in the absorption route. Conventional cannabinoid oils enter through portal venous circulation and undergo extensive first-pass hepatic metabolism. MFG-encapsulated cannabinoids follow the physiological pathway evolved for dietary fat absorption: enterocyte uptake, chylomicron assembly, and secretion into intestinal lacteals. The chylomicrons drain via the thoracic duct into systemic circulation before reaching the hepatic portal system. NATURIA PLUS™ is covered by U.S. Patent No. 11,291,700 B2.
Contains milk. The NATURIA PLUS™ platform is built from milk fat globule membrane. Every product label discloses milk as an allergen in compliance with federal FALCPA requirements. Do not use if you have a dairy allergy or milk protein sensitivity.
Two peer-reviewed human crossover studies establish the multi-fold bioavailability improvement of SNEDDS cannabinoid delivery over standard oil formulations.
Knaub et al. (2019) reported 4.4-fold higher peak concentration (Cmax) and 2.85-fold higher total exposure (AUC) versus MCT-oil reference, with time-to-peak reduced from approximately three hours to approximately one hour. n=16, randomized crossover, healthy adults (Molecules 24(16):2967).
Hermush et al. (2025) replicated the effect in a more recent crossover RCT, demonstrating 2.3 to 3.2-fold relative bioavailability improvements for THC, CBD, 11-OH-THC, and 7-OH-CBD when comparing a SNEDDS powder versus oil drops in 14 healthy volunteers (J Cannabis Res 7:24).
Across the two human studies, the published clinical evidence supports a 3x to 5x design target for SNEDDS cannabinoid bioavailability versus unformulated standard oils.
How to read this: the 3x to 5x range reflects published human pharmacokinetic data on SNEDDS cannabinoid formulations in the same delivery class as NATURIA PLUS™. The Knaub and Hermush studies tested SNEDDS-class formulations, not the NATURIA PLUS matrix specifically. Larger figures reported in preclinical rat models (Izgelov 2020, Cherniakov 2017) have not been replicated in human studies.
In May 2026, researchers from the University at Buffalo, the University of Michigan, and the analytics firm MoreBetter published a peer-reviewed real-world evidence study in Clinical Therapeutics examining cannabinoid capsule compositions delivered via lipid-based delivery technology in the same class as NATURIA PLUS™.
168 adults with fibromyalgia, rheumatoid arthritis, or osteoarthritis received a 12-week supply of cannabinoid capsule compositions and completed validated questionnaires assessing pain, mood, sleep, and physical functioning.
The researchers reported significant improvements across nearly every symptom domain measured. Effect sizes ranged from small to large. In their own conclusion, "nonintoxicating cannabinoids such as CBD and CBDa may provide relief from pain and related symptoms and may be utilized when cannabis intoxication is undesirable or problematic."
How to read this: this was a real-world evidence study, not a randomized placebo-controlled trial. The cannabinoid capsules studied were manufactured by LEVEL and Overcome and used lipid-based delivery technology in the same class as NATURIA PLUS™. The study did not directly test Axon Ritual products. Citation: Kruger DJ, Dautrich T, Hall B, Keeling K, Provost K, Boehnke KF. Assessing the Efficacy of Cannabinoid Compositions for Treating 3 Classes of Chronic Pain: A Real-World Evidence Study. Clin Ther. 2026 May 15. doi: 10.1016/j.clinthera.2026.04.018. PMID: 42140793.
Every ingredient and delivery claim on this site is anchored to PubMed-indexed research. The library is organized by category so you can see what each study contributes and what it does not. Representative citations shown below. Full bibliography available on request.
Human crossover pharmacokinetic studies on the self-emulsifying delivery system used in our formulations, and closely-related lipid-based platforms. These studies characterize the delivery mechanism. They do not evaluate the finished Axon Ritual products.
Systematic reviews and controlled human studies that establish the baseline problem NATURIA PLUS is designed to solve: cannabinoids taken as unformulated oils are poorly absorbed. These studies establish the context. They do not describe our specific formulation.
Peer-reviewed evidence on the individual functional botanicals and cannabinoids used in Genesis, Hypnos, and Ether. These studies inform structure-function reasoning for each formulation. They are not evaluations of the finished Axon Ritual products.
Representative individual-ingredient citations are indexed with each ritual on the Rituals section of the Home page and in the full bibliography. Consult the bibliography for the complete list.
The scientific reasoning that guided the design of each ritual, including target endpoints, cannabinoid ratios, and the choice of accessory botanicals. Formulation rationale is published on the Compliance page and detailed per product at launch.
Formulation rationale documents are prepared per product and available on request for retail partners and healthcare practitioners. Contact info@axonritual.com.
Every production batch is tested by an independent ISO-accredited laboratory. Certificates of Analysis are indexed by product and batch number at /coa/. Testing scope: cannabinoid potency, residual solvents, heavy metals, pesticides, mycotoxins, and microbiologicals.
See our COA library for current batch results and our Compliance page for testing methodology.
Full bibliography available on request · All studies PubMed-indexed
Bibliography last reviewed Q3 2026. Re-verified annually against Google Scholar and Clarivate JCR.
Axon Ritual products are produced under current Good Manufacturing Practices in an FDA-registered, cGMP-certified facility. Every batch is tested by an accredited third-party laboratory for cannabinoid content, heavy metals, residual solvents, pesticides, and microbial contamination.
Certificates of Analysis are linked to each batch and accessible by serial number from any product page. Transparency is structural, not optional.
The first production run is limited. Founding access closes when public availability begins.
Axon Ritual products are intended for adults of legal age in a U.S. jurisdiction where cannabinoid hemp products are lawful.